Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zafirlukast in cat dander-induced allergic rhinitis
NCT06069063Phase 2Not yet recruiting
- Sponsor
- Allergy & Asthma Medical Group & Research Center
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of zafirlukast in allergic rhinitis (AR), sponsored by Allergy & Asthma Medical Group & Research Center. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
zafirlukast
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06069063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06069063.